Press Releases - Oxford Biomedica

John Dawson named Executive of the Year for Companies <$10bn at the Annual Scrip Awards 2020

-Ends- Oxford, UK – 3 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, John Dawson,…

Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19

Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) announced AZD1222 met primary…

Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director

Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, with effect from…

Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration

Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability PhoreMost’s SITESEEKER platform will identify active peptides to be deployed within Oxford Biomedica’s LentiVector® delivery system Oxford, UK…

Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD

Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes Axovant Gene Therapies’ (“Axovant”) positive six-month follow-up…

Oxford Biomedica receives MHRA approval for fourth manufacturing suite in Oxbox

Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that the UK Medicines & Healthcare…

Oxford Biomedica plc interim results for the six months ended 30 June 2020

Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six…

Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19 Vaccine Candidate, AZD1222

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this…

Notice of Interim Results

Oxford, UK – 27 August, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, will be announcing its interim results for the…

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics

Oxford, UK – 3 August 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new…

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD

Oxford, UK – 31st July, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a three…

Oxford Biomedica notes interim results from AstraZeneca on AZD1222 showing strong antibody and T-cell responses and acceptable safety profile

Oxford, UK – 20 July, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes that AstraZeneca UK Ltd (“AstraZeneca”) has announced…